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ABSTRACT
This research focuses on examining the neurological similarities between schizophrenia
and major depressive disorder with psychotic features in order to compare the manifestations of
psychosis in each disorder. Both disorders often involve symptoms of psychosis, although the
overall disorders are very different from each other. The hypothesis for this research is that the
neurological similarities between schizophrenia and major depressive disorder with psychotic
features will provide researchers with the strategies needed to develop a treatment for psychotic
symptoms. In order to test this hypothesis, five related studies were gathered for each disorder,
and three studies were gathered for psychosis. These studies were then analyzed to pinpoint any
similarities among factors for psychosis, and this analysis allowed for the determination of whether
or not the hypothesis would be rejected. The results indicated that a lot of the similarities between
the two disorders cannot be verified because of the lack of substantial research.
Keywords: psychosis, schizophrenia, major depressive disorder with psychotic features
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INTRODUCTION
Schizophrenia and major depressive disorder with psychotic features (MDD-PF) are
psychological disorders in which patients experience psychotic symptoms, also called psychosis.
These symptoms include delusions, hallucinations, and in some cases incoherent speech or
inappropriate behavior. Psychosis can be a scary experience, seeing as it involves what is often
described as a “loss of touch” with reality. It can be difficult for a person experiencing psychosis
to recognize when their experiences are not consistent with reality. If left untreated, psychosis can
lead to social decline, paranoia, and neurological damage. Therefore, early treatment is important
as it can lead to a better prognosis. If the possible causes for psychosis are pinpointed, this could
lead to the development of a treatment for psychosis, potentially improving prognosis at all stages
of development.
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OBJECTIVE
The purpose of this research is to identify similarities between schizophrenia and MDDPF. These disorders were chosen due to the fact that they are distinct enough from each other that
any similarities may offer significance for potential causes. Other psychotic disorders such as
schizoaffective disorder and bipolar disorder share a greater number of similarities with
schizophrenia compared to MDD-PF. The vast difference between disorders is important because
any factors that are shared may be directly related to psychosis, which is the most prominent
feature that the disorders share. Factors that are compared include epidemiology, symptoms,
treatment mechanisms, and prognosis. Any similarities between the two disorders may have
significant implications for the treatment of psychotic symptoms, considering that psychosis is
present in both disorders. The disorders are different enough from each other that any similarities
may offer insight into potential diagnoses and treatments. It is likely that the causes for psychosis
will be observable when examining the molecular backgrounds and neurological manifestations
for each disorder. Psychosis is a symptom in which patients often experience a disconnection from
reality (e.g., delusions or hallucinations). The causes for psychosis are not known, although there
are theories that will be explored throughout this research. Because psychosis is displayed in the
psychiatric disorders described, it is likely that the causes for psychosis will manifest in these
disorders. Ideally, the potential causes for psychosis will be observable when the disorders are
being analyzed. The hypothesis for this research is that the neurological similarities between
schizophrenia and MDD-PF will provide researchers with strategies to develop a treatment for
psychotic symptoms.
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BACKGROUND
Psychosis is said to represent the “severe” end of schizophrenia [1], seeing as schizophrenia
is often thought to encompass some of the most damaging aspects of psychosis. Schizophrenia can
be described as a transient disconnection from reality. MDD-PF is a form of major depression in
which psychotic symptoms are often present. While thought to not be as “severe” as schizophrenia,
it can also have some damaging effects. In both cases, it is important that symptoms are managed
and treatment is ongoing. With proper treatment and emotional support, patients are able to live
healthy and successful lives.
SYMPTOMS, EPIDEMIOLOGY, AND DIAGNOSIS
Schizophrenia
Patients with schizophrenia experience two types of symptoms: positive and negative.
Positive symptoms are perceptions that are not normally present in the general population, such as
hallucinations and delusions. Negative symptoms occur when perceptions that are normally
present in the general population are absent. This can include reduced emotional expression (i.e.,
constricted/flat affect), and reduced motivation (i.e., avolition) [11]. According to the Diagnostic
and Statistical Manual of Mental Disorders, 5th edition (DSM-5), individuals must experience
symptoms for a period of at least six months in order to be diagnosed with schizophrenia.
Causes for this disorder are still being researched, although there are believed to be genetic
and environmental risk factors. It is, however, difficult to determine whether specific
environmental factors can lead to the development of schizophrenia or if these factors simply cooccur with the disorder. For this reason, it is practical to think of environmental factors as potential
risk factors rather than causes. There are three different “levels” of risks: highest-level risk,
3

intermediate risk, and lower-level risk [14]. The highest-level risk factors can involve having a
direct relative with schizophrenia or having a parent who is an immigrant from a certain country.
These factors appear to have more significance in the development of schizophrenia compared to
intermediate and lower level risks. Intermediate risks can involve being born or raised in an urban
area, having had a father over the age of fifty-five at the time of birth, and having minor physical
abnormalities [2]. Lower-level environmental risk factors include the exposure to certain harmful
agents prior to birth. For example, studies show that if a woman smokes while she is pregnant,
there is an increased risk that the child will suffer from schizophrenia. This is similarly the case
when a fetus is exposed to maternal stress. Interestingly, studies indicate that children born during
the winter or early spring seasons experience a 10% increase in risk for developing schizophrenia
[3]. Additionally, there is a strong association between maternal herpes simplex virus type 2
antibodies and development of psychotic symptoms later in life. Children who are at risk for
schizophrenia may have an increased risk if exposed to influenza during the mother's first trimester
of pregnancy. One important thing to note is that a lot of these factors are simply correlated with
the disorder; they do not indicate direct causes.
Some potential risk factors can occur after birth, such as childhood sexual abuse and
traumatic brain injury. Ongoing use of cannabis in the early adolescent years (prior to age 16)
is shown to accelerate one's risk of experiencing psychosis, as this leads to increased levels of
dopamine [12]. In some cases, those who are susceptible develop marijuana-induced psychosis.
The regular use of marijuana during early adolescence can therefore be thought of as a potential
risk factor for schizophrenia. Another factor that may increase one’s risk for developing this
disorder is withdrawal from social interaction. Studies show that those who isolate themselves are
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at a higher risk for developing the disorder. In order to reduce one's risk of developing
schizophrenia, individuals should avoid social isolation and seek psychological intervention if
initial signs begin to occur, such as behavioral changes and fragmented psychotic symptoms [13].
This is especially important if there is a family history of schizophrenia, as this is shown to be
correlated with higher-level risk. It is not certain whether a person must be genetically predisposed
in order to develop the disorder.
Childhood environment also plays an important role in the development of psychotic
symptoms. In an Israeli study that examined childhood-rearing and its links to psychiatric
disorders, researchers concluded that at-risk children who were raised in family environments were
less likely to develop a psychiatric disorder compared to children who were raised in kibbutz
environments. Children who have atypical interactions with their mothers also experience a greater
risk for developing schizophrenia later in life. Psychotic symptoms are likely to be experienced by
individuals who have grown up in unstable or abusive homes [14]. This does not indicate that
childhood abuse causes psychotic symptoms, but the correlation indicates that certain
environments can play a role in whether or not psychotic symptoms develop. Head injury is also a
potential risk factor for psychotic symptoms. In the case of a head injury, because the brain is
affected, a type of psychosis known as organic psychosis may occur. This is also true for cases of
infections or illnesses that affect the brain [14].
In order to be diagnosed with schizophrenia, patients can undergo physical examinations,
screenings to rule out conditions with similar symptoms, and psychiatric evaluation [7].
Individuals should also meet the diagnostic criteria listed in the Diagnostic and Statistical Manual
of Mental Disorders (DSM-5).
5

MDD-PF
MDD, commonly called clinical depression, is a mood disorder in which patients
experience constant sadness that interferes with normal functioning. MDD-PF, also known as
psychotic depression, is considered a subset of MDD in which patients sometimes experience
psychosis during a depressive episode. Some symptoms for the disorder include fatigue or loss
of energy, social isolation, difficulty concentrating, and insomnia or hypersomnia [15]. Symptoms
may differ slightly depending on the age of the patient. The epidemiology is variable, since it is
not known exactly what causes psychotic depression. Biological changes in one’s brain,
neurochemistry, and genetics are thought to play a role. Certain symptoms for MDD-PF may be
associated with neurotransmitter imbalance. Researchers believe that imbalances in dopamine and
glutamate may be present in both MDD-PF and schizophrenia, although further testing is required
in order to confirm this. Genetic factors play an important role in the disorder, as studies
have shown that genetic offspring are more likely to suffer from MDD-PF, as opposed to adopted
children with no family history of depression. Twin studies have indicated that twins have a
heritability of approximately 40-50% [5]. Poor physical health and traumatic life events are
associated with MDD-PF, indicating that environmental factors can play a minor role. However,
based on existing research, genetics appear to have the largest influence over whether or not an
individual will develop the disorder.
As mentioned previously, the use of cannabis during adolescence has been correlated with
an increased risk of psychotic symptoms due to higher concentrations of dopamine being secreted.
However, depression is typically associated with decreased levels of dopamine, so it is difficult to
say whether cannabis use during the early teenage years can lead to the development of psychosis
6

in MDD-PF. Environmental factors are limited in cases of MDD-PF, mainly due to the lack of
substantial research on the disorder. Psychosocial factors have been shown to play a role. One’s
social environment can have an effect on the development of psychosis in MDD-PF, as social
isolation is generally sh own to increase risk [8]. Some other factors that can lead to the
development of psychosis mirror the environmental risk factors for schizophrenia. Child abuse and
maternal separation can lead to the development of psychosis in individuals who are
susceptible. Demographics indicate that MDD-PF is more common in older women and in African
and Caribbean migrants [8].
According to the DSM-5, patients must experience a minimum of five of the listed
symptoms for a period of at least two weeks in order to be diagnosed with MDD. Because
depression tends to co-occur with chronic diseases, physicians may run lab tests or do physical
examinations on patients who show symptoms. For example, in the case of hypothyroidism, an
underactive thyroid may cause patients to feel depressed and fatigued [16]. It is common for
doctors to fail to diagnose hypothyroidism due to depressive symptoms being present, so it is
important that a blood test is done in order to rule out this possibility. Physical examinations may
also be conducted in order to rule out underlying physical health issues (i.e., diabetes or high blood
pressure). A psychiatric evaluation may be used to diagnose the disorder.
BIOLOGICAL FACTORS
As is the case with most psychiatric disorders, there are biological factors that affect the
development and manifestation of both disorders. Schizophrenia and MDD-PF are believed to be
influenced by both genetics and environment, although the extent to which they are influenced by
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these factors is not known. Because genetics have an influence on each disorder, it is important to
examine the biological factors that are involved.
Schizophrenia
Schizophrenia may include an imbalance in certain neurotransmitters. Some of these
neurotransmitters include dopamine, which is responsible for motivation and reward, and
glutamate, the primary excitatory neurotransmitter [4]. Neuroimaging can provide information
about how the disorders relate to differences in the brain structure and/or function and can assist
researchers with understanding the neurobiology behind each disorder. This aids in the
development of treatments and in diagnostic procedures. A MRI study of monozygotic twins in
which one was affected by schizophrenia and one was not showed that those affected by
schizophrenia have larger ventricles. This is also true of those who are unaffected carriers [4].
Studies have also shown that those who suffer from schizophrenia have smaller
hippocampal volumes. Change in hippocampal structure is associated with early stress, as the
hippocampus is responsible for stress regulation [4]. Additionally, reduced white and gray
matter are structural characteristics for schizophrenia. Individuals with schizophrenia may
also exhibit deficiencies in parts of the brain that depend on the prefrontal cortex (PFC) [4]. This
explains why working memory and interference control are sometimes impaired in
individuals who suffer from this disorder.
Biological risk factors can start as early as before birth, as minor physical anomalies
(MPAs) are thought to play a role in developmental disorders. MPAs have been observed to have
an increased prevalence in schizophrenic patients. Nutritional factors (i.e., low levels of vitamin
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D) may also play a role in the development of psychosis [2]. However, these potential risk factors
do warrant further research in order to determine whether they cause psychotic symptoms.
MDD-PF
MDD-PF has a heritability of approximately 40% [5]. This is likely due to the molecular
genetics and pathophysiology of MDD. However, research on molecular genetics is fairly limited
for cases of MDD-PF. Based on available clinical and pharmacogenetics studies, it is thought that
MDD-PF is heavily influenced by genetics. Linkage studies indicate that there is an overlap
between specific genetic risks for depression and schizophrenia. In a study of patients with MDD,
it was discovered that the brain derived neurotropic factor (BDNF) val66met polymorphism has
an association with psychotic features [6]. In contrast to MDD without psychotic features,
additional genes were found to be associated with cases of MDD in which psychotic features were
present. Some of these genes include single nucleotide polymorphisms in the dysbindin (DTNBPI)
gene, the A allele of the 444G/A variant in the dopamine beta-hydroxylase (DBH) gene, and the
active allele of the monoamine oxidase A (MAO-A) variable number of tandem repeats (VNTR)
[6].
Postmortem and neuroimaging studies have shown that reductions in grey matter and glial
density in the PFC and hippocampus are characteristic of depression. High amounts of cortisol in
MDD-PF may be explained by decreased hippocampal function, because this is thought to inhibit
the hypothalamic-pituitary-adrenal (HPA) axis [9]. The amygdala is also affected in cases of
MDD-PF [9]. This disorder is not as well-researched as other, more common psychological
disorders, so there are many potential risk factors that have not been investigated. For example,
MPAs and neurological soft signs (NSSs) are associated with schizophrenia and may be associated
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with psychosis, but have not been investigated in cases of MDD-PF [9]. Depressive symptoms can
occur due to physical health problems, (i.e., hypothyroidism, reduced estrogen levels, and
disrupted circadian rhythms).
TREATMENTS AND PREVENTION
There is no cure for either schizophrenia or MDD-PF, so various treatment methods are
often used. These treatment methods include and are not limited to antipsychotics, antidepressants,
electroconvulsive therapy, and cognitive behavioral therapy.
Schizophrenia
Treatments for schizophrenia often involve medications and psychosocial therapy. There
is no cure so many patients continue to receive treatment over the course of their lives. However,
there have been cases in which patients with schizophrenia experience spontaneous remission and
no longer require treatment. Studies show that in cases of schizophrenia in which patients have
made a full recovery, about 12 to 22% of these patients experience one single episode of
schizophrenia [13]. Treatment is often guided by a psychiatrist along with a treatment team.
Hospitalization may be necessary in extreme cases. Electroconvulsive therapy (ECT) may be
considered effective for patients who do not respond to drug therapy. Some of the medications that
are typically used for drug therapy can be put into two categories: first-generation and secondgeneration antipsychotics [7]. Research has shown that second-generation antipsychotics may be
associated with increased efficacy in the treatment of major depressive disorder [32]. Patients who
use second-generation antipsychotics appear to show slight improvements in overall symptoms
compared to first-generation antipsychotics. In particular, medications such as olanzapine,
amilsulpride, and risperidone appear to be associated with an improved quality of life. Evidence
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also indicates that there may be a smaller degree of side effects associated with certain secondgeneration antipsychotics compared to first-generation antipsychotics. This may be dependent on
the specific drug that is being used because some second-generation antipsychotics have shown
associations with increased sedation or weight gain.
Psychosocial therapy includes individual or family therapy, social skills training, or
vocational rehabilitation. As mentioned previously, avoiding social isolation and seeking
intervention if there are any early signs of schizophrenia can aid in prevention. Other methods for
prevention include developing social skills, learning coping mechanisms to deal with anxiety and
depression, and learning how to view the world more optimistically.
MDD-PF
Similarly to schizophrenia, there is no permanent cure for MDD-PF, but there are measures
that can be taken to manage the symptoms. These include medications, psychotherapy,
hospitalization, and brain stimulation therapies. Antidepressants in combination with
antipsychotic medications may help treat the disorder, although these medications may not be
effective until months after a patient begins taking them. A common medication that is used to
treat MDD-PF is selective serotonin reuptake inhibitors (SSRIs), which are antidepressants
that increase serotonin levels and are often used in combination with antipsychotics [17].
Psychotherapy involves learning cognitive and behavioral skills to alleviate symptoms with a
mental health professional. If MDD-PF is severe, typically if patients begin harming themselves
or attempting to commit suicide, hospitalization may be necessary. ECT, which is also sometimes
used to treat schizophrenia, is a form of brain stimulation therapy that may be utilized to treat
MDD-PF. Prevention of the initial onset of MDD may be possible. If a person is at risk for
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depression, undergoing cognitive or behavioral therapies may be beneficial. However, prevention
of depression has not been studied extensively and it is a difficult disorder to prevent due to the
genetic factors being so prominent.
Newer forms of treatment may be developed following the discovery of new information
regarding each disorder, including previously unknown causes and molecular markers. Molecular
markers are crucial, because they may aid in identifying an alteration in genetic expression that
causes susceptibility to the disorder.
PROGNOSIS
For both schizophrenia and MDD-PF, prognosis is largely dependent upon the individual.
Prognosis can be affected by a number of factors, including the severity of symptoms, how early
intervention begins, and genetic predisposition.
Schizophrenia
The prognosis for schizophrenia is better when onset of the disorder is acute and treatment
begins early. Other factors that are associated with good prognosis include demonstrating good
premorbid functioning, being married, and exhibiting prominent affective features [13]. If
treatment begins late and/or onset is more severe, the prognosis is grimmer. However, with proper
treatment, those who have schizophrenia are able to live healthy, happy lives.
MDD-PF
Unfortunately for those who suffer from MDD-PF, the prognosis does not appear to be
favorable. MDD-PF is thought to be a debilitating disorder with a high likelihood of recurrence.
Because of this, it is important that patients undergo long-term treatment in order to avoid relapse.
According to a study in which patients were examined over the course of two years, 58% of
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patients recovered from MDD-PF while 21% had a chronic episode. The same study was
conducted over the period of six years, in which 17% of patients experienced recovery and over
55% had chronic episodes [10]. While prognosis can be dependent on the individual, statistical
data indicates that a higher percentage of patients tend to experience relapse over a longer period
of time. Prognosis is largely dependent on when treatment begins, and in order for treatment to be
effective, it must be ongoing. Individuals who suffer from the disorder are likely to experience
relapse.
PSYCHOSIS
Psychosis, rather than being its own psychological disorder, is a symptom that can occur
within various neurological and psychiatric disorders. Causes are varied depending on the
psychological disorder in which it manifests. In the cases of schizophrenia and MDD-PF,
psychosis appears to be mainly genetic. Traumatic life events and consistent marijuana usage
during early adolescence may lead to the development of psychosis, but some theories have
speculated that individuals must be genetically predisposed in order to develop these symptoms
[6]. Antipsychotics can effectively reduce psychotic symptoms in specific disorders, but they do
not treat the underlying illness. Typical antipsychotics, also called first-generation antipsychotics,
are usually less expensive than second-generation drugs, and they have been around for a longer
period of time. It is not known which of these types of treatment is more effective, although some
evidence suggests that second-generation antipsychotics may be associated with more improved
symptoms.
Dopamine and glutamate imbalance may be crucial factors in psychotic symptoms. It is
thought that the psychopathology for psychosis is influenced by imbalance in dopaminergic
13

activity. Glutamate abnormalities have also been shown to play a role in psychosis [9]. Because
both of these neurotransmitters are involved in schizophrenia, MDD-PF, and psychosis, they may
play a major role in the development of psychosis. Examining the biological factors for these
imbalances may aid in recognizing common features for the two disorders.
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SIGNIFICANCE
As stated previously, psychosis can have damaging effects in those who are affected. If left
untreated, more severe health problems such as neurological damage may occur. Psychotic
symptoms involve delusions, hallucinations, and paranoia, all of which have associations with
being “out of touch” with reality. These can be scary for patients to experience and can often
interfere with normal functioning. For this reason, it is important that psychotic symptoms are
treatable. Because psychosis often requires ongoing treatment, it would benefit those who suffer
from psychotic symptoms if a permanent cure were to be developed. By examining two slightly
distinct disorders and comparing their manifestations of psychotic symptoms, the potential causes
for psychosis can be identified. From here, treatments that target these specific causes would be
able to be developed.
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METHODOLOGY & AIMS
This research involves a meta-analysis and systematic review approach, in which
schizophrenia and MDD-PF and compared in order to pinpoint commonalities. Five related studies
were gathered for each disorder, and three studies were gathered for psychosis as a symptom.
Additional studies involving both disorders were also examined. These studies were analyzed to
pinpoint any similarities between factors for psychosis, and this analysis allowed for the
determination of whether or not the hypothesis would be rejected. Because this research
emphasizes the causes for psychosis, the studies mainly focus on specific causes. This approach
was taken because, by combining data from multiple studies and by isolating data from previous
studies, any existing biases in previous research can be minimized. Using this method, reliable
conclusions can be drawn. Several studies involving MDD-PF, schizophrenia, and psychosis were
examined individually and then combined in order to analyze the consistency of the data presented.
As stated in the hypothesis, the aim is to identify similarities that are significant enough to
potentially be used in the development of a treatment for psychosis. Some of the factors that were
compared include neurological similarities, cognitive effects, and pathophysiology for each
disorder. Additionally, structural changes, neurotransmitter imbalance (i.e., dopamine and
glutamate), and diagnostic methods were contrasted. Epidemiology and treatment mechanisms
were also compared. The DSM-5 was frequently referenced throughout the research process, in
addition to numerous peer-reviewed journal articles.
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STUDIES
In order to test the hypothesis for this research, recent studies were compared in order to
determine whether the similarities between the two disorders were significant. In order to be
considered significant, the similarities between the disorders need to offer substantial potential
causes and additional features for psychosis. These potential causes and other features do not need
to be various. They should simply show a reasonable amount of potential to positively influence
the development of treatments. Studies that focused on the neurobiological factors for each
disorder were examined. Specifically, the structural changes, molecular genetics, and functional
impairments were examined for each disorder.
SCHIZOPHRENIA
Study 1: Neuropathology of Schizophrenia [20]
Some of the structural abnormalities that have been observed in schizophrenia include a
decrease in cerebral volume and widening of the lateral and third ventricles. Cerebral weight is
observed to be decreased as well. MRI studies have indicated especially large reductions in brain
volume in the temporal lobe and in medial temporal structures, including the hippocampus and
amygdala. Structural imaging also indicates that grey matter is more reduced compared to white
matter. There is speculation that patients with schizophrenia have a reduction in the size of the
thalamus. It has also been reported that patients experience structural abnormalities in the
cerebellum, although further research must be done to confirm either of these theories.
Study 2: Dopamine Hypothesis of Schizophrenia: Version III – The Final Common Pathway [21]
This hypothesis seeks to explore the question of whether symptoms in schizophrenia are
related to dysfunctions in the regulation of dopamine. There is emphasis on the possibility that
17

dopamine may play a dominant role in psychosis. Version III is the most recent version of this
hypothesis since it accounts for the most recent knowledge about dopamine’s role in
schizophrenia. It is expected to be revised in the future as research continues to be conducted on
factors associated with schizophrenia. This study emphasizes the fact that there are environmental
factors correlated with schizophrenia that cannot be explained by genetics. For example, it has
been observed that increased dopaminergic activity can result from factors such as social isolation.
Because both genetic and environmental factors are shown to play a role in dopamine
dysregulation in schizophrenia, it is thought that these factors work together to influence
dopaminergic functions. This in turn may have an effect on symptoms in schizophrenia.
Study 3: Molecular Genetics of Schizophrenia [27]
This study focuses on linkage studies, neurotransmitter responses, and other factors in
order to observe the molecular genetics of schizophrenia. Neurotransmitters such as dopamine,
serotonin, and glutamate have been shown to have a role in schizophrenia. Amino acids such as
glycine and cysteine also have manifestations in the disorder. The D3 dopamine receptor gene is
present in high concentrations in the limbic system so it may have a large role in schizophrenia.
However, studies have not been able to confirm the dopamine theory. Glutamate appears to show
evidence of an association with schizophrenia. Patients with schizophrenia display reduced nonNDMA glutamate receptors in the temporal lobe compared to individuals who do not have
schizophrenia. Studies have also demonstrated that patients with schizophrenia have reductions in
serotonin receptors in the PFC. The serotonin transporter gene is also shown to be involved with
psychosis. It is possible that other neurotransmitters such as GABA are associated with
schizophrenia, but existing evidence is too weak to allow for any conclusions to be made.
18

Study 4: Prefrontal Functioning during Context Processing in Schizophrenia and Major
Depression [29]
It has been observed that patients with schizophrenia exhibit decreased cerebral blood flow
in the prefrontal cortex, called hypofrontality. This study seeks to find out whether hypofrontality
occurs only in schizophrenia or if it manifests in other psychotic disorders. Results indicated that
patients with schizophrenia exhibit larger reductions in cognition than patients with non-psychotic
depression. It is uncertain whether dysfunctions related to context processing in the prefrontal
cortex are specific to cases of schizophrenia, or if these dysfunctions appear in other psychiatric
disorders.
Study 5: Cognitive Impairments in Psychotic Disorders [18]
This study asserts that patients with schizophrenia experience a higher degree of
impairment to cognitive abilities compared to patients with MDD-PF and other psychiatric
disorders such as bipolar disorder. These disorders do still involve an impairment to cognitive
function, but the impairment is less severe than as observed in schizophrenia. In the case of
schizophrenia, working and episodic memory are affected, partly due to the fact that the prefrontal
cortex is impaired and has difficulty communicating with other regions of the brain. Schizophrenia
appears to display a higher amount of cognitive impairment than affective psychosis, although the
overall degree of cognitive impairment seen in schizophrenia and psychosis is very similar. Results
indicate that all psychotic disorders involve cognitive damage at some level.
MDD-PF
Study 1: Clinical and Molecular Genetics [23]
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This study explores the inheritance of psychotic depression with reference to family
studies, other psychotic disorders, and molecular genetics including pharmacogenetics studies.
Dopamine has been observed to play a role in the development of MDD-PF. The dopamine betahydroxylase gene is reported to show lower plasma levels in patients with psychotic depression
when compared to patients with nonpsychotic depression. Glutamate may be linked to MDD-PF
but it is not certain whether increased or decreased glutamate concentration is associated with the
onset of the disorder. Serotonin receptors and transporter have been shown to not have an
association with MDD-PF. Genetic and family studies do indicate that psychotic depression is
often inherited and may be heavily influenced by genetics. This highlights part of the reason why
it is so important that genetic research continues to be conducted on this disorder.
Study 2: Structural and Functional Neuroimaging Studies in Major Depressive Disorder with
Psychotic Features [25]
This study focuses on the pathophysiology for psychotic disorders such as MDD-PF and
schizophrenia, with a particular emphasis on MDD-PF. Structural changes in patients with MDDPF are observed in proportion to changes in MDD without psychotic features. One structural
change seen only in MDD-PF patients involves a reduction in the size of the amygdala. Enlarged
ventricles and reductions in the volume of the prefrontal cortex were also observed. A distinction
in structural features between MDD-PF and schizophrenia includes a reduction in size of the
posterior subgenual cingulate cortex (in the medial side of the cerebral cortex) in patients with
MDD-PF. There is evidence that dysfunctions in dopamine may be present in cases of MDD-PF,
although the extent to which this influences the disorder is unknown.
Study 3: Cortisol Activity and Cognitive Changes in Psychotic Major Depression [26]
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This study built on the fact that MDD-PF is a distinct disorder rather than simply a subset
of MDD. While this disorder is technically a subset of MDD, there are features present that are not
present in MDD, indicating that MDD-PF can be considered to be distinct from MDD without
psychotic features. In this study, patients with MDD, patients with MDD-PF, and individuals
without psychiatric disorders were each given a memory test. Memory was shown to be worse in
patients with MDD-PF than in either of the other groups. Studies also indicate that patients with
MDD-PF have greater degrees of cognitive impairments that those with MDD without psychotic
features. This includes problems with prefrontal functions and memory.
Study 4: Hippocampal and Amygdalar Volumes in Psychotic and Nonpsychotic Unipolar
Depression [30]
According to this study in which the hippocampal and amygdalar volumes in patients with
major depressive disorder (MDD) without psychotic features and MDD-PF were compared, it was
demonstrated that patients with MDD-PF had much smaller amygdalar volumes. The amygdalar
volume in patients with MDD was shown to be similar to healthy subjects. There was no significant
difference in hippocampal volumes between the groups.
Study 5: Dopaminergic Function and the Cortisol Response to Dexamethasone in Psychotic
Depression [31]
This study tested the hypothesis that psychotic symptoms in MDD-PF could result from
increased dopamine activity. After the cortisol and hormonal responses to DST suppressors and
activators were examined, the conclusion was that psychotic symptoms in MDD-PF do not appear
to be related to dopamine regulation.
PSYCHOSIS
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Study 1: Disconnection between Amygdala and Medial Prefrontal Cortex in Psychotic Disorders
[22]
A common characteristic that appears in psychotic disorders is an impairment in cognitive
functioning, including deficits in memory and reduced amygdalar functioning. These factors are
enhanced in response to distracting emotional information such as unemployment. When patients
who suffer from psychotic disorders experience an emotional distractor, a reduction in connectivity
between brain regions has been observed, with a particular increase in reduction of brain structures
in cases of schizophrenia.
Study 2: Dopamine and Psychosis [24]
Studies have shown that psychosis may be triggered by a dysfunction in dopamine
synthesis, as stated in the dopamine hypothesis of schizophrenia. This study focuses on the links
between psychosis and dopamine activity. Some studies suggest that psychosis is affected by
factors other than dopamine activity such as prefrontal functioning. There are implications that
these additional factors occur alongside dopamine dysfunction. Schizophrenia’s link with
psychosis and dopamine was extensively researched in this study, and results indicate that
excessive dopamine activity may lead to the cognitive impairments seen in schizophrenia. These
impairments include those that occur in working memory, abstract reasoning, and other cognitive
functions that rely on the prefrontal cortex. Based on the results that were gathered in this study,
it is plausible that dopamine plays a central role in the psychotic symptoms seen in schizophrenia
and other psychotic disorders.
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Study 3: Progressive Brain Structural Changes Mapped as Psychosis Develops in ‘At Risk’
Individuals [28]
This study emphasizes findings that indicate that individuals who are at risk for developing
psychotic disorders display progressive structural changes in the brain prior to developing the
disorder. Results indicate that those who experience psychosis demonstrate much greater changes
in brain structure in the prefrontal cortex than any other region of the brain, even before symptoms
of a psychotic disorder developed. This implies that reductions in the volume of the prefrontal
cortex may be associated with the development of psychosis.
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RESULTS
It is important to note that patients with MDD-PF exhibit a reduction in size of the posterior
subgenual cingulate cortex, while patients with schizophrenia do not. Because this feature is not
seen in either schizophrenia or psychosis, it is likely the result of depressive features rather than
psychotic features. This emphasizes the fact that patients with MDD-PF are less likely to display
certain psychotic features compared to schizophrenia, since MDD-PF has an additional feature
(depression) that is not displayed in either schizophrenia or psychosis. This distinction enables
effective comparison of certain features in order to determine whether or not they are significant,
since the disorders are different enough that any similarities they have may be significant for the
hypothesis.
The factors that were compared when examining the studies include structural changes,
molecular backgrounds, and other biological factors. Multiple studies have concluded that there
are changes in brain volume in schizophrenia as well as in MDD-PF. Specifically, it has been
shown that amygdalar volume as well as hippocampal volume are reduced in patients with
schizophrenia. Patients with MDD-PF have been shown to have large reductions in amygdalar
volume, but no significant changes in hippocampal structure compared to those who are not
affected with MDD without psychotic features. Whether or not this decrease in amygdalar volume
is significant is largely dependent on whether psychosis as a symptom is affected by structural
changes in the amygdala. Based on existing research, a reduced amygdalar volume does appear to
be related to psychosis, so this factor could plausibly be considered significant. Other structural
changes that are observed in both disorders include enlarged ventricles and reduction in volume of
the prefrontal cortex. Because these factors are consistent in both disorders and in psychosis as a
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symptom, they may be significant for the hypothesis. However, in order to be considered
significant, there must be additional supporting data since these structural brain changes may be
associated with another common denominator.
Table 1: Structural Brain Changes Associated with Schizophrenia and MDD-PF
Brain Structure

MDD-PF

Schizophrenia

Cerebrum

Reduced blood flow

Reduced blood flow

Prefrontal cortex

Reduction in volume

Reduction in volume

Amygdala

Reduction in volume

Reduction in volume

Hippocampus

No significant change

Reduction in volume

Posterior subgenual cingulate Reduction in volume

No significant change

cortex
Ventricles

Enlarged

Enlarged

Thalamus

No significant change

Possible association

Cerebellum

No significant change

Possible association

White matter

Disrupted

Reduced

Gray matter

Disrupted

Reduced to a higher degree
compared to white matter

The molecular backgrounds for each disorder include associated neurotransmitters and
hormones. One study concluded that dopamine dysregulation is not related to psychotic symptoms
in MDD-PF. This is in contrast to the dopamine hypothesis of schizophrenia, in which it is thought
that dopamine dysregulation may have a role in the development of schizophrenia. However, there
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is another study that concluded that dopamine dysregulation may be associated with MDD-PF, but
this study specifically highlighted reduced concentrations of dopamine having an association.
Schizophrenia, on the other hand, is associated with increased dopamine secretion. This study does
not offer reliable evidence that MDD-PF is indeed associated with decreased dopamine secretion
because another study concluded that the linkage may be insignificant or even nonexistent. Since
dysfunctions in dopamine activity in MDD-PF patients may not be related to psychosis, it cannot
be concluded that dopamine is a direct cause for psychosis, regardless of dopamine’s association
with psychosis in other psychotic disorders. Because the research regarding dopamine’s role in
MDD-PF is relatively limited, it is possible that dopamine has a larger role that has not been studied
yet. This may especially be the case since the dopamine hypothesis of schizophrenia highlights the
fact that current evidence is consistent with the possibility of dopamine dysfunction playing a
central role in psychosis. Since this is only a speculation, the dopamine hypothesis is not significant
enough to support the hypothesis for this research. Other neurotransmitters such as serotonin and
glutamate were shown to have greater effects in one disorder compared to the other, or had
associations that were not consistent with each other. Therefore, this factor can be disregarded as
a supporting factor for the hypothesis.
Table 2: Molecular Structures Associated with Schizophrenia and MDD-PF
Molecular Structure

MDD-PF

Schizophrenia

Cortisol

Increased concentrations

Increased concentrations

Serotonin transporter

No association

Reduced

Serotonin receptor 1A

No association

Reduced

Serotonin receptor 2A

No association

Reduced
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Table 2: Molecular Structures Associated with Schizophrenia and MDD-PF
Serotonin receptor 2C

No association

Reduced

Dopamine beta-hydroxylase

Decreased concentrations

Decreased concentrations

D1 receptor

Possible reduction

May be associated with
reductions in the prefrontal
cortex

D2 receptor

Possible reduction

Increased concentrations

D3 receptor

Possible reduction

Increased concentrations;
weak association

5-hydroxytrytamine; 5HT

No association

Findings are inconsistent but
indicate a possible association
with negative symptoms and
ventricular enlargement

Glutamate

and

Glutamine Possible association

combined

Increased concentrations
especially as patients age;
associated with positive
symptoms

Dopamine transporter

Possible reduction

No association

Non-NDMA glutamate

Possible association

Reduced

receptors
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Cognitive impairments are associated with both schizophrenia and MDD-PF, although
patients with schizophrenia display higher degrees of damage. On its own, psychotic symptoms
are associated with cognitive impairments that have very similar profiles to the impairments
displayed in schizophrenia. Since these impairments in psychosis are more similar to schizophrenia
than to MDD-PF, it is difficult to say whether this factor could be considered significant for the
hypothesis. It is possible that those with MDD-PF display diminished amounts of cognitive
impairment because psychotic features are a “smaller portion” of the disorder compared to
schizophrenia. Patients with MDD-PF often experience psychotic symptoms in addition to
depression, which sets it apart from both schizophrenia and psychosis. Schizophrenia, on the other
hand, is almost considered to be synonymous with psychosis, so it is expected that schizophrenia
and psychosis would display a greater amount of similar features. However, because this
possibility is hypothetical, cognitive impairment will not be considered as a significant supporting
factor.
In terms of epidemiology, symptoms, and prognosis, any similarities would be considered
insignificant because these factors would not reasonably provide information needed that would
aid in the development of permanent treatments. Treatments would be best developed to target
certain neurotransmitters or structural deficiencies in the brain. It would not be practical to expect
a treatment to potentially be derived based on information related to epidemiology and similar
factors. Current treatments can offer insight into ways that symptoms can be managed but the
development of cures is mainly dependent on genetic research.
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CONCLUSION
Based on the information that was gathered, the hypothesis for this research must be
rejected. Unfortunately, the amount of existing research regarding the disorders, especially MDDPF, is very limited. Because of this, many of the similarities between MDD-PF and schizophrenia
are speculative rather than definite. With so many gray areas in current research, it is difficult to
pinpoint exactly what needs to be targeted in the treatment of psychosis. The hypothesis may
possibly be more strongly supported in the future after substantial research is conducted on each
disorder. For the time being, there is not enough available information for any reliable conclusions
to be drawn regarding possible treatments.
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DISCUSSION
Both schizophrenia and MDD-PF appear to be affected by both genetic and environmental
factors, although the extent to which each disorder is affected is unknown. MDD-PF has
demonstrated a high degree of heritability so it is possible that the disorder is more strongly
affected by genetics compared to environmental factors. Psychosis is also shown to be affected by
genetics and environment. Because of this, it was important to address both the genetic and
environmental risk factors for each disorder when conducting this research. The genetic
similarities are more likely to offer support for the hypothesis, considering the fact that medicinal
treatments can directly target biological factors such as structural abnormalities and
neurotransmitter imbalance. Environmental factors are better treated with psychological therapies
and cannot be directly targeted.
Some of the similarities that have been pinpointed include structural abnormalities and
neurotransmission. Patients with MDD-PF and patients with schizophrenia demonstrate reduced
prefrontal volumes, smaller amygdalar structures, and dilated ventricles. Dopamine may have
associations with each disorder although further research must be conducted in order to confirm
this. Serotonin and glutamate are shown to have associations with schizophrenia and either reduced
or no associations with MDD-PF. With regards to cognitive impairments and the effects of
dopamine, the differences between the disorders outweigh the similarities. While both disorders
display deficits in cognitive functioning and dysregulation of dopamine, the disorders are not
affected to the same extent and certain factors manifest themselves in different ways.
Due to the limitations in current research, there are a lot of uncertainties and hypotheticals
when examining the similarities between MDD-PF and schizophrenia. For example, the structural
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abnormalities could hypothetically be a cause for psychosis assuming that there is no other
common denominator. Since it is not known whether these abnormalities are associated with a
completely different aspect of each disorder, it is best to reject this as a potential cause. Although
the hypothesis was rejected, this does not mean that it will never be supported by data or that it
will always be rejected. Considering that the largest problem when gathering data was that there
is a lack of considerable research, the hypothesis may be better supported in the future, assuming
that substantial research will be done on both disorders, as well as on psychosis on its own.
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LIMITATIONS
There is currently a lack of considerable research regarding psychosis and MDD-PF.
Schizophrenia has been researched more thoroughly, but there is still a lot that is not known about
the disorder. Because this research was based primarily on existing research, it was at times
difficult to find exact data regarding the biological background for schizophrenia and MDD-PF.
Many of the potential genetic causes for the disorders were not definite causes; rather, they were
considered potential risk factors or associated factors. Additionally, some environmental factors,
potential causes, and diagnoses for each disorder, as well as for psychosis, were under-researched.
Because of this, many of the comparisons made throughout this research were hypothetical and
unconfirmed.
One other limiting factor in this research is the fact that a lot of studies relate psychosis
directly to schizophrenia. This made it difficult to find studies that focused primarily on psychosis.
For example, many studies referenced the dopamine hypothesis of schizophrenia and some studies
had a slight implication that dopamine dysregulation was related to psychotic symptoms. However,
this may only be the case for some psychotic disorders, since one study indicated that it was
unlikely that the psychotic symptoms in MDD-PF are associated with dopamine dysregulation.
This lack of research on psychosis on its own made it difficult to compare symptoms of psychosis
in MDD-PF and schizophrenia, since psychosis and schizophrenia were often studied so closely
in relation to each other.
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